DSC and physico-chemical properties of a substituted pyridoquinoline and its interaction study with excipients

  • D. Abbas
  • J. Kaloustian
  • C. Orneto
  • P. Piccerelle
  • H. Portugal
  • A. Nicolay
Article
First Online:
Received:
Accepted:

Abstract

The 4,6-bis[2′(diethylamino)ethoxy]2,8,10-trimethylpyrido[3,2-g]quinoline (BG 637) is one of the compound from the pyrido[3,2-g] quinolines family. This compound had in vitro activity against the resistant cells and can reverse the multidrug resistance developed during the chemotherapeutic treatments.

To characterize BG 637, techniques such as differential scanning calorimetry (DSC), Fourier transform infrared spectrometer (FTIR), ultra violet spectrophotometry (UV), gas chromatography coupled with mass spectrometry (GC/MS), nuclear magnetic resonance (NMR) and X-ray powder diffraction (XRPD) were used. Several of them were also used to show the stability of the drug during various storage conditions.

DSC, FTIR and UV were used as screening techniques for assessing the compatibility of BG 637 with several commonly used pharmaceutical excipients. We compared the properties of the pure drug with those of binary mixture drug/excipient. Studied excipients were lactose monohydrate, microcrystalline cellulose, polyvinylpyrrolidone, sodium croscarmellose and magnesium stearate. Melting temperature and enthalpy of BG 637 in binary mixtures were similar to theoretical values. These results showed that BG 637 is a very stable compound and compatible with several pharmaceutical excipients.

Keywords

BG 637 DSC excipients interactions physico-chemical properties stability 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    E. Teodori, S. Dei, S. Scapecchi and F. Gualtieri, Il Farmaco, 57 (2002) 385.CrossRefGoogle Scholar
  2. 2.
    M. Volm and J. Mattern, Crit. Rev. Oncog., 7 (1996) 227.Google Scholar
  3. 3.
    P. Olliaro, Pharmacol. Ther., 89 (2001) 207.CrossRefGoogle Scholar
  4. 4.
    T. Tsuruo, H. Iida, S. Tsukagoshi and Y. Sakurai, Cancer Research, 41 (1981) 1967.Google Scholar
  5. 5.
    C. Matias, A. Mahamoud, J. Barbe, B. Pradine and J. C. Doury, Heterocycles, 43 (1996) 1621.CrossRefGoogle Scholar
  6. 6.
    ICH Harmonised Tripartite Guideline, Stability Testing of New Drug Substances and Products, ICH Q1A(R2). The European Agency for the Evaluation of Medicinal Products (CPMP/ICH/2736/99), 2003.Google Scholar
  7. 7.
    R. C. Rowe, P. J. Sheskey and P. J. Weller, Handbook of Pharmaceutical Excipients, 4th Ed., Pharmaceutical Press (PhP) and American Pharmaceutical Association (APhA), London and Chicago 2003.Google Scholar
  8. 8.
    A. R. Gennaro, Ed., Remington’s Pharmaceutical Sciences, 18th Ed., Mack Publishing Company., Easton PA 1990.Google Scholar
  9. 9.
    A. E. Aboutaleb, A. M. Attia and F. S. Habib, Pharmazie, 38 (1983) 473.Google Scholar
  10. 10.
    H. A. Liebermann, L. Lachman and J. B. Schwartz, Pharmaceutical Dosage Forms: Tablets, 2nd Revised and Expanded Ed., 1996.Google Scholar
  11. 11.
    O. A. Itiola and N. Pilped, Int. J. Pharm., 31 (1986) 99.CrossRefGoogle Scholar
  12. 12.
    S. Y. Lin, J. Pharm. Sci., 77 (1988) 229.CrossRefGoogle Scholar
  13. 13.
    Z. T. Chowhan, Pharm. Technol., 17 (1993) 72.Google Scholar
  14. 14.
    P. C. Mora, M. Cirri and P. Mura, J. Pharm. Biomed. Anal., 42 (2006) 3.CrossRefGoogle Scholar
  15. 15.
    A. A. Araujo, S. Storpirtis, L. P. Mercuri, F. M. Carvalho, M. dos Santos Filho and J. R. Matos, Int. J. Pharm., 260 (2003) 303.CrossRefGoogle Scholar
  16. 16.
    EDQM and European Directorate for the Quality of Medicines and Health Care, European Pharmacopoeia, 6th Ed., Council of Europe, Strasbourg 2008.Google Scholar
  17. 17.
    I. I. Jivraj, L. G. Martini and C. M. Thomson, Pharm. Sci. Technol. Today, 3 (2000) 58.CrossRefGoogle Scholar
  18. 18.
    United States Pharmacopoeia-National Formulary, USP 30-NF 25, Rockville 2007.Google Scholar
  19. 19.
    C. L. Winek, Drugs Pharm. Sci., 103 (2000) 59.Google Scholar
  20. 20.
    ICH Harmonised Tripartite Guideline, Impurities: Residual Solvents, ICH Q3C(R3). The European Agency for the Evaluation of Medicinal Products (CPMP/ICH/283/95), 1997.Google Scholar
  21. 21.
    P. Bracconi, C. Andres, A. N’Diaye and Y. Pourcelot, Thermochim. Acta, 429 (2005) 43.CrossRefGoogle Scholar
  22. 22.
    P. Bracconi, C. Andres and A. N’Diaye, Int. J. Pharm., 262 (2003) 109.CrossRefGoogle Scholar
  23. 23.
    S. Sharpe, M. Celik, A. Newman and H. Brittain, Struct. Chem., 8 (1997) 73.CrossRefGoogle Scholar
  24. 24.
    P. Crowley and L. Martini, Pharm. Technol. Eur., 13 (2001), 26–28 see also 30–32, 34.Google Scholar
  25. 25.
    S. Byrn, R. Pfeiffer, M. Ganey, C. Hoiberg and G. Poochikian, Pharm. Res., 12 (1995) 945.CrossRefGoogle Scholar
  26. 26.
    H. G. Brittain, S. J. Bogdanowich, D. E. Bugay, J. DeVincentis, G. Lewen and A. W. Newman, Pharm. Res., 8 (1991) 963.CrossRefGoogle Scholar
  27. 27.
    ICH Harmonised Tripartite Guideline, Pharmaceutical Development, ICH Q8. The European Agency for the Evaluation of Medicinal Products (CPMP/ICH/167068/04), 2005.Google Scholar
  28. 28.
    G. G. G. Oliveira, H. G Ferraz and J. S. R. Matos, J. Therm. Anal. Cal., 79 (2005) 267.CrossRefGoogle Scholar
  29. 29.
    M. Laszcz, B Kosmacinska, K. Korczak, B. Simigielska, M. Glice, W. Maruszak, A. Groman, H. Beczkowicz and L. Zelazko, J. Therm. Anal. Cal., 88 (2007) 305.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • D. Abbas
    • 1
  • J. Kaloustian
    • 2
  • C. Orneto
    • 1
  • P. Piccerelle
    • 1
  • H. Portugal
    • 2
  • A. Nicolay
    • 2
  1. 1.Laboratoire de Pharmacie Galénique, Pharmacotechnie Industrielle, Biopharmacie et Cosmétologie, Faculté de PharmacieUniversité de la MéditerranéeMarseille Cedex 05France
  2. 2.Laboratoire de Chimie Analytique, Qualitologie, Nutrition; U.M.R. INSERM 476-INRA 1260, Faculté de PharmacieUniversité de la MéditerranéeMarseille Cedex 05France

Personalised recommendations